The United States Department of Defense (DOD) awarded Moderna a contract valued at $1,966,598,000 for an additional 100 million doses of the company’s Covid-19 vaccine.

Pfizer Inc. and BioNTech SE announced that the U.S. Food and Drug Administration authorized the emergency use of the mRNA vaccine, BNT162b2, against Covid-19 in individuals 16 years of age or older.

Inovio Pharmaceuticals Inc. dosed the first participant in a mid-stage clinical trial testing the company’s Covid-19 vaccine candidate, INO-4800.

Inovio Pharmaceuticals Inc. received clearance from the U.S. health regulatory agency to begin a mid-stage study of the company’s Covid-19 vaccine candidate, the vaccine maker said.

U.S. coronavirus infections surged by at least 129,606, according to a Reuters tally, the third consecutive daily rise of more than 100,000 cases as a third wave of Covid-19 sweeps the United States.

With rising numbers of COVID-19 infections and as the fight against the novel coronavirus continues, Novavax received $1.6 billion in federal funding to support the clinical development of the company’s vaccine candidate NVX‑CoV2373.

Regeneron Pharmaceuticals received a $450 million contract to manufacture and supply a two-antibody cocktail for the treatment and prevention of COVID-19 as part of Operation Warp Speed from the Biomedical Advanced Research and Development Authority (BARDA).

23andMe announced that the company was laying off about 100 employees as sales were down, reflecting a shrinking market for DNA test kits to consumers.

Abbott announced the next phase of partnership with the U.S. Department of Defense and researchers from the Transforming Research and Clinical Knowledge in Traumatic Brain Injury (TRACK-TBI) Network, one of the largest traumatic brain injury efforts of its kind.

The CEO of Platelet BioGenesis sees a future in the development of an on-demand platelet product made from stem cells.